You are here
Articles of Interest: Vaccines
I implore you to do something, because we can do something. - Tamika Felder
Let's End HPV-related Cancers: A Congressional Briefing
American Association for Cancer Research
Herper, Matthew. "FDA approves Gardasil 9, the HPV vaccine, to prevent head-and-neck cancer." STAT News, June 12,2020.
For the past decade, evidence has suggested that Gardasil, the HPV vaccine, could stem an epidemic of throat cancer. But it has also never received approval from the Food and Drug Administration for that use — and it was unclear if it ever would.
On Friday, the agency granted that approval, clearing the latest version of the vaccine, Gardasil 9, to prevent a cancer that affects 13,500 Americans annually. The decision was announced by Gardasil’s maker, Merck.
Firth, Shannon. "Vaccine Access, Hesitancy Amid COVID-19." MedPage Today, June 3, 2020.
Overcoming vaccine hesitancy and access issues has become even more critical because of the COVID-19 pandemic, public health experts argued at a recent webinar hosted by the National Academies of Sciences, Engineering, and Medicine.
Walker, Molly. "Many Parents Shun CDC's Vax Schedule for Kids - Opting for delaying or skipping vaccines instead." MedPage Today, February 21, 2020.
More than one-third of parents did not follow the recommended vaccination schedule for their young children in 2014, opting for a different schedule that included delaying or skipping vaccines, researchers found.
Jenkins, Kristin. "Evidence Grows for One-Dose HPV Vaccination." MedPage Today, February 11, 2020.
Even a single dose of the quadrivalent human papillomavirus (4vHPV) vaccine was associated with lower incidence of pre-invasive cervical disease compared with no vaccination in adolescent women, according to researchers.
In a large retrospective matched cohort study involving women age 15-19, risk of histologically confirmed cervical intraepithelial neoplasia II/III (CIN-II/III) was equivalent with one, two, or three doses of 4vHPV vaccine. The adjusted hazard ratios (HRs) were 0.64, 0.72, and 0.66, respectively, all with statistical significance.
Jenkins, Kristin. "Is One HPV Vaccine Dose Enough? -- NHANES data suggest yes, but researchers urge caution." MedPage Today, January 2, 2020.
A single-dose vaccination regimen for human papillomavirus (HPV) had similar efficacy against HPV infection compared with the recommended two- or three-dose series, although researchers caution that more research is needed.
Loftus, Eileen Glanton. "Let's End HPV-related Cancers: A Congressional Briefing." American Association for Cancer Research, June 28, 2019.
Every two minutes, a woman somewhere in the world dies of cervical cancer.
That harrowing statistic, shared by Anna R. Giuliano, PhD, founding director of the Center for Immunization and Infection Research in Cancer at the Moffitt Cancer Center in Tampa, Florida, reflects a great frustration in public health. There is a vaccine that prevents infection with the virus that can cause cervical cancer and several other cancer types, yet worldwide, not enough people are taking advantage of it.
"FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old." US Food and Drug Administration Press Release, October 5, 2018.
The U.S. Food and Drug Administration today approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) expanding the approved use of the vaccine to include women and men aged 27 through 45 years. Gardasil 9 prevents certain cancers and diseases caused by the nine HPV types covered by the vaccine.
"Parents See Cancer Prevention Potential as Best Reason for HPV Vaccination." American Association for Cancer Research, June 14, 2018.
Parents of adolescents believed that the potential to prevent certain types of cancer is the best reason for their children to receive the human papillomavirus (HPV) vaccine, whereas other reasons health care providers often give were far less persuasive, according to results published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
"MD Anderson and nation’s top cancer centers endorse goal of eliminating HPV-related cancers." MD Anderson News Release, June 7, 2018.
Joint statement encourages parents, young adults and physicians to take advantage of vaccination to prevent future HPV-related cancers
Michael D. Becker as told to Jo Cavallo. "HPV-Related Cancers Like Mine Are Avoidable, So Why Aren’t More Kids Being Vaccinated?." ASCO Post, May 10, 2018.
The latest news from the Centers for Disease Control and Prevention about vaccination rates in the United States for human papillomavirus (HPV) is disappointing. It shows that in 2016, just 43.4% of adolescents (49.5% of females and 37.5% of males) were up-to-date with the recommended 3-dose HPV vaccination series,1 which is far below the U.S. Department of Health and Human Services Healthy People 2020 goal of 80% coverage.2 Each year, HPV causes about 41,000 cases of cancer in the United States,3 and I’m sorry to say I am among its victims.
Lyman, Stewart. "The HPV Vaccine: Preventing Cancer Beats Treating It." Lyman BioPharma Consulting, LLC, March 5, 2018.
You don’t have to be an oncologist to know that fighting cancer is tough. Nearly 1.7 million Americans will be diagnosed with cancer this year, and about 600,000 will die from the disease. But here’s some good news: overall U.S. cancer deaths have been in a steep decline for over 25 years. Much of this reduction is tied to a decline in smoking, along with early detection of some cancers (e.g. colon), and more effective cancer therapies. While treatments against some particular types of cancer have advanced greatly, it’s still a disease no one wants to face. Fighting an opponent that you can never be really sure you’ve defeated challenges both the physical strength and mental fortitude of those who’ve been diagnosed. I know because I’ve been there.
"NCI’s Douglas R. Lowy and John T. Schiller to receive 2017 Lasker Award." September 6, 2017.
Two scientists at the National Cancer Institute (NCI) will receive the 2017 Lasker-DeBakey Clinical Medical Research Award for their significant research leading to the development of human papillomavirus (HPV) vaccines.